A 55-year-old man with multidrug-resistant Staphylococcus aureus bacteremia is started on daptomycin. Two days later he develops worsening dyspnea. Chest radiograph demonstrates new bilateral infiltrates, and sputum culture grows the same MRSA strain. Which property of daptomycin best explains its failure to treat this pulmonary infection?
- The drug is inactivated by pulmonary surfactant, preventing membrane depolarization of bacteria in the lung (correct answer)
- The drug cannot penetrate the outer membrane of Gram-positive cocci residing within alveolar macrophages
- The acidic pH of alveolar fluid protonates the drug, abolishing its binding to bacterial ribosomes
- The drug requires anaerobic conditions to be converted to its active free-radical form in lung tissue
Explanation: When you encounter questions about antibiotic failure in specific anatomical locations, consider how the local environment might interfere with drug mechanisms. This question tests your understanding of daptomycin's unique mechanism and why it fails specifically in pulmonary infections. Daptomycin works by binding to bacterial cell membranes in a calcium-dependent manner, causing membrane depolarization and bacterial death. However, pulmonary surfactant—a phospholipid-rich substance that reduces surface tension in alveoli—directly binds to and inactivates daptomycin. This prevents the antibiotic from reaching bacterial cell membranes to cause depolarization, explaining why the same MRSA strain that was treatable in the bloodstream now causes pneumonia despite continued therapy. Looking at the incorrect options: Choice B incorrectly suggests daptomycin needs to penetrate outer membranes of Gram-positive bacteria, but Gram-positive organisms lack outer membranes (that's a Gram-negative feature), and daptomycin targets the cytoplasmic membrane directly. Choice C wrongly describes daptomycin as binding to ribosomes—this describes protein synthesis inhibitors like aminoglycosides, not daptomycin's membrane-targeting mechanism. Choice D incorrectly suggests daptomycin requires anaerobic activation to form free radicals, which describes metronidazole's mechanism, not daptomycin. Remember this key clinical pearl: daptomycin should never be used for pneumonia, regardless of in vitro susceptibility, because pulmonary surfactant reliably inactivates it. On USMLE Step 1, when you see daptomycin failing specifically in lung infections, think surfactant inactivation—this is a high-yield concept that frequently appears on exams.